Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial

Leukemia

Volumn 31, Issue 3, 2017, Pages 734-738

  Edelmann, J ^a,b   Tausch, E ^a   Landau, D A ^c,d,e   Robrecht, S ^f   Bahlo, J ^f   Fischer, K ^f   Fink, A M ^f   Bloehdorn, J ^a   Holzmann, K ^a   Bottcher S ^g   Werner, L ^c   Kneba, M ^g   Gribben, J G ^b   Neuberg, D S ^c   Wu, C J ^c   Hallek, M ^f   Dohner H ^a   Stilgenbauer, S ^a  

^a UNIVERSITY OF ULM   (Germany)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NEW YORK GENOME CENTER   (United States)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN P53; RITUXIMAB; TP53 PROTEIN, HUMAN;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL OUTCOME; COPY NUMBER VARIATION; GENETIC VARIATION; HUMAN; LETTER; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; CELL CLONE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

CLONE CELLS; DNA COPY NUMBER VARIATIONS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; RITUXIMAB; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85000956475     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.317     Document Type: Letter

References (14)

1. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
2. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525-530.
3. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
4. Ouillette P, Saiya-Cork K, Seymour E, Li C, Shedden K, Malek SN. Clonal evolution, genomic drivers, effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res 2013; 19: 2893-2904.
5. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
6. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104: 20007-20012.
7. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
8. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473-4479.
9. Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, et al. Highresolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012; 120: 4783-4794.
10. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013; 122: 2673-2682.
11. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013; 210: 2273-2288.
12. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988.
13. Bassaganyas L, Beà S, Escaramís G, Tornador C, Salaverria I, Zapata L, et al. Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Leukemia 2015; 29: 758.
14. Ernst A, Jones DT, Maass KK, Rode A, Deeg KI, Jebaraj BM, et al. Telomere dysfunction and chromothripsis. Int J Cancer 2016; 138: 2905-2914.